Post-Test Evidence-Based Approaches to Clinical Pathway Development for Metastatic Urothelial Cancer Post-Test Based on a recent analysis, the rate of which of the following was significantly reduced within an oncology care model using evidence-based clinical pathways? Drug spending Insurance reimbursement Prior authorizations Treatment discontinuation Enfortumab vedotin, an FDA-approved antibody-drug conjugate for cisplatin-ineligible mUC, targets which of the following proteins? FGFR Nectin-4 PD-L1 TROP-2 Based on the phase 3 EV-301 trial, enfortumab vedotin monotherapy was FDA-approved following which of the following treatment(s)? A pan-FGFR inhibitor Another antibody-drug conjugate Any checkpoint inhibitor Platinum-containing therapy or a PD-1 or PD-L1 inhibitor Patients treated with enfortumab vedotin should be monitored for which of the following adverse events? Anemia Hyperglycemia Hyperphosphatemia Neutropenia Please rate your understanding of the complexities associated with clinical pathways in the therapeutic landscape of metastatic urothelial cancer. Excellent Very good Good Fair Poor Please rate your level of confidence in translating the latest evidence, expert recommendations, and available cost data into improved urothelial cancer clinical pathway development. Very confident Confident Somewhat confident Not very confident Not at all confident Previous
